Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.

The study findings could help predict which patients will develop resistance to PARP inhibitors and allow doctors to alter treatment at the earliest possible opportunity.

The Institute of Cancer Research, London, has been recognised with a highly prestigious Queen’s Anniversary Prize for its world-leading research in cancer drug discovery.